One hundred and thirty-one patients were transplanted for AML-CR1, ALL-CR1 or CML-CP1 after conditioning with 120 mg/kg body weight cyclophosphamide and 2 ؋ 4.5 Gy TBI. Conditioning was intensified with the addition of 42 mg/m 2 idarubicin. Grafts were T celldepleted using counterflow centrifugation. Donors were HLA-identical siblings. We compared outcome of BMT in 109 patients aged less than 50 (median, 35) years with that of 22 patients with an age of 50 years or more (median, 53 years). For the patients aged Ͻ50 years, 2-year probabilities of treatment-related mortality, relapse, survival and leukemia-free survival were 26% (95% CI, 17% to 35%), 26% (95% CI, 17% to 35%), 64% (95% CI, 55% to 73%), and 56% (95% CI, 47% to 65%). For the patients aged у50 years, these figures were 13% (95% CI, 0% to 30%), 24% (95% CI, 6% to 42%), 66% (95% CI, 46% to 86%), and 67% (95% CI, 47% to 87%), respectively. Outcome did not differ significantly between the two age groups. TRM was within the range of that reported in the literature for recipients of T cell-depleted grafts. We conclude that T cell-depleted transplantation after a conditioning regimen that was intensified with the addition of idarubicin is feasible in patients aged у50 years. For this age group of patients, results of nonmyeloablative regimens should be compared with that obtained with T cell-depleted grafts. Bone Marrow Transplantation (2000) 26, 17-22. Keywords: T cell-depleted transplantation; intensified conditioning regimen; patients aged у50 years Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in recipients of bone marrow transplants.
ditioning regimen by the addition of anthracyclines. This intensified regimen was not associated with a higher transplant-related mortality (TRM). 6 Recently, other approaches to allografting have been developed consisting of conditioning regimens that are reduced in intensity. These nonmyeloablative regimens enable engraftment and mixed chimerism and consequently reduce GVHD. However, in patients treated for malignancies, full allogeneic donor chimerism has to be accomplished by the infusion of lymphocytes from the original donor. Preliminary studies have shown that this approach in patients treated for malignancies is associated with substantial morbidity and mortality. 7, 8 In the present analysis we demonstrate that conditioning with an intensified regimen followed by T cell-depleted BMT remains feasible for older patients and outcome can compete with that in younger patients.
Patients and methods
From June 1986 to January 1999, 131 patients were transplanted for AML-CR1, ALL-CR1 or Philadelphia chromosome (Ph chromosome)-positive CML-CP1 with grafts that were depleted of 98% of lymphocytes by counterflow centrifugation. 9 In all these patients conditioning consisted of idarubicine (42 mg/m 2 by continuous infusion), cyclophosphamide (120 mg/kg) and 2 ϫ 4.5 Gy TBI. 10 All donors were HLA-A, B, DR identical and MLC negative or HLA-A, B, DRB and DQB-identical siblings. Patients were divided into two groups according to age: 109 patients were Ͻ50 years and 22 patients aged 50 years or more. The median number of CD3 ϩ cells infused in the patients Ͻ50 years was 0.9 (range, 0.1-3.2) ϫ 10 6 /kg body weight and 0.8 (range, 0.6-1.4) ϫ 10 6 /kg in the patients of у50 years (P ϭ 0.37). All patients were managed in single rooms with air filtered under positive pressure during their hospital stay. They received oral selective gut decontamination consisting of ciprofloxacin 500 mg orally twice daily, as well as co-trimoxazole for Pneumocystis carinii prophylaxis and oral acyclovir for prophylaxis of herpes infection. Characteristics of patients and donors are given in Table 1 .
Median follow-up for the younger patients was 38 (range, 0-161) months and 18 (range, 5-93) months for patients aged у50 years (P ϭ 0.28). 
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Immunoprophylaxis after transplantation
All patients received cyclosporine A (CsA) 3 mg/kg body weight/day by continuous intravenous infusion from days Ϫ1 to ϩ14, followed by 2 mg/kg body weight/day by continuous intravenous infusion on to day 21. After day 21, CsA was given orally at a dose of 6 mg/kg body weight/day until 12 weeks after transplantation. Beyond 12 weeks CsA was gradually tapered off and discontinued at 16 weeks. Acute graft-versus-host disease (GVHD) was classified grade 1 to 4 according to Glucksberg et al 11 and chronic GVHD as limited and extensive following the Shulman et al 12 criteria.
Definitions
The first day of engraftment was defined as the first of 3 consecutive days with peripheral blood leukocyte counts of у1.0 ϫ 10 9 /l. Non-engraftment was defined as primary failure if WBC never reached 1.0 ϫ 10 9 /l or as secondary if WBC reached 1.0 ϫ 10 9 /l on 3 or more consecutive days and disappeared after further follow-up. Treatment-related mortality was defined as death while in continuous complete remission. Relapse was defined as the reappearance of clinical features and laboratory findings compatible with the underlying leukemia (hematologic relapse) or as the reappearance of the Ph chromosome in CML patients (cytogenetic relapse) with or without hematologic relapse.
Follow-up ended on 1 December 1999. This means that for surviving patients follow-up was at least 11 months.
Statistics
The chi-square test was used for comparison of categorical variables. The Mann-Whitney U test was used to compare continuous variables. The probabilities of relapse, survival and leukemia-free survival (LFS) were calculated using the Kaplan-Meier method. Differences in probabilities were calculated using the log-rank test. The Kaplan-Meier method was also used for the calculation of the probability of current LFS. For this calculation, patients who relapsed and attained further remission after the infusion of lymphocytes from the original donor (DLI) 13 were not scored for relapse. Probability of current LFS was calculated from BMT onwards and was given only for the endpoint of follow-up. Calculations were made using the Statistica Release 4.1 programme (Apple Computer, Cupertino, CA, USA). P values Ͻ0.05 were considered significant.
Results
Engraftment
Two patients (both Ͻ50 years) died within 18 days after transplantation and were not evaluable for engraftment. Take failure occurred in two of 107 patients (2%) aged Ͻ50 years (one primary and one secondary) and in none of the 22 patients у50 years. The 107 patients aged Ͻ50 years engrafted at 10 to 49 (median, 18) days and the 22 patients with an age у50 years engrafted at 11 to 30 (median, 17) days (P ϭ 0.23).
GVHD
Acute GVHD уgrade 2 developed in 28 of 128 patients (22%) at risk. Acute GVHD уgrade 2 occurred in 26 of 106 patients (25%) aged Ͻ50 years and in two of 22 patients (9%) with an age of у50 years (P ϭ 0.11). Acute GVHD grade 3 or 4 occurred in seven of 128 patients (5%). Acute GVHD grade 3 or 4 was found in seven of 106 patients (7%) aged less than 50 years and in none of the patients of у50 years old (P ϭ 0.21).
Chronic GVHD occurred in 58 of 116 patients (50%) with a follow-up of more than 3 months and was limited in 45 patients (39%) and extensive in 13 (11%). Limited chronic GVHD was observed in 34 of 94 patients (36%) aged Ͻ50 years and in 11 of 22 patients (50%) with an age of 50 years or more (P = 0.23). Extensive chronic GVHD occurred in 11 of 94 patients (12%) younger than 50 years and in two of 22 patients (9%) aged у50 years (P ϭ 0.73).
Mortality
Fifty-one of 131 patients (39%) died after transplantation. Forty-three of 109 patients (39%) aged less than 50 years died and death occurred in eight of 22 patients (36%) aged 50 years or more (P ϭ 0.78). Principal causes of death in the younger patient group were relapse (n ϭ 18), infection (n ϭ 13), GVHD (n ϭ 7), and one case each of cerebral hemorrhage, hemolyic uremic syndrome, cirrhosis of the liver, primary and secondary take failure. For the patients aged у50 years principal causes of death were relapse (n ϭ 3), and one case each of GVHD, infection and secondary lymphoma.
Thirty-five of 131 patients (27%) died within 1 year after transplantation and in 24 of 131 patients (18%) mortality was treatment-related. Overall 1-and 2-year probabilities of treatment-related mortality (TRM) were 20% (95% CI, 13% to 27%) and 24% (95% CI, 16% to 32%), respectively. For the patients younger than 50 years, 1-and 2-year TRM were 22% (95% CI, 14% to 30%) and 26% (95% CI, 17% to 35%), respectively. In the patients у50 years these probabilities were 6% (95% CI, 0% to 17%) and 13% (95% CI, 0% to 30%), respectively (P ϭ 0.11 and 0.21, respectively). Follow-up of the patients у50 years was shorter than that in patients younger than 50 years and improvement in TRM in the last few years might have influenced outcome. All patients aged у50 years were transplanted from February 1992 onwards. One-and 2-year probabilities of TRM in the 58 patients aged Ͻ50 years and transplanted from February 1992 onwards were 19% (95% CI, 11% to 27%) and 23% (95% CI, 14% to 32%). The differences in the 1-and 2-year probabilities of TRM did not differ significantly between the two age groups transplanted from February 1992 onwards (P ϭ 0.19 and 0.33, respectively).
Relapse
Thirty-four of 131 patients (26%) relapsed after BMT. Three CML patients had only cytogenetic relapse at 6, 18 and 47 months and all were Ͻ50 years. Among the relapsed patients were 27 of 109 patients (25%) younger than 50 years and seven of 22 (32%) aged у50 years (P ϭ 0.49). The 2-year probability of relapse was 26% (95% CI, 17% to 35%) and 24% (95% CI, 6% to 42%) for the patients aged Ͻ50 and у50 years, respectively (P ϭ 0.79) and is shown in Figure 1 . Eleven CML patients Ͻ50 years relapsed. Two relapsed in blastic phase, one died without further treatment and the second patient died from sepsis after DLI. Nine patients (one in acceleration, five in chronic phase and three with only cytogenetic relapse) attained further complete hematologic and cytogenetic remission after DLI. Two CML patients of 50 years or more relapsed in blastic phase and chronic phase, respectively. They were given DLI. The patient in blastic phase died without any response and the other entered further complete hematologic and cytogenetic remission.
Survival
Eighty of 131 patients (61%) patients were alive at 11 to 161 (median, 66) months and survivors were 66 of 109 No. patients at risk > 50 years No. patients at risk < 50 years <50 years
>50 years
Figure 1 Probability of relapse in the patients aged Ͻ50 years and those with an age of у50 years. P ϭ 0.26.
Bone Marrow Transplantation patients (61%) aged less than 50 years and 14 of 22 patients (64%) with an age of 50 years or older (P ϭ 0.78). The 2-year probabilities of survival in the patients Ͻ50 and у50 years were 64% (95% CI, 55% to 73%) and 66% (95% CI, 46% to 86%), respectively (P ϭ 0.72). Kaplan-Meier survival curves are given in Figure 2 .
Leukemia-free survival
Probabilities of leukemia-free survival (LFS) are shown in Figure 3 . For the younger patient group, the 2-year probability of LFS was 56% (95% CI, 47% to 65%) and was 67% (95% CI, 47% to 87%) for the patients aged 50 years or more (P Ͼ 0.05). When we corrected LFS for the nine relapsed CML patients Ͻ50 years and for the patient у50 years who attained further complete remission after DLI, current LFS projected at the end of follow-up was 58% (95% CI, 48% to 68%) in the younger patient group and 59% (95% CI, 36% to 82%) in the group of patients у50 years (P Ͼ 0.05). Kaplan-Meier curves for current LFS are given in Figure 4 . Significantly more patients aged Ͻ50 years were transplanted for ALL (see Table 1 ) and probabilities of LFS may differ between disease categories. Table 2 shows that probabilities of LFS did not differ significantly between patients transplanted for AML, ALL and CML.
Discussion
Ringdén et al 14 reported on outcome after HLA-identical sibling bone marrow transplantation for AML, ALL or CML in 2180 patients divided into four cohorts based on age (30 to 39 years, 40 to 44 years, 45 to 49 years and patients of у50 years). In 80% of cases conditioning regimen included TBI. Twenty-four percent of patients received T cell-depleted grafts. After transplantation for early leukemia (AML-CR1, ALL-CR1 and CML-CP1), no significant differences were found in the 2-year probabilities for TRM, relapse and LFS between the four age cohorts. In the present analysis we confirmed these findings Bone Marrow Transplantation No. patients at risk > 50 years No. patients at risk < 50 years <50 years
>50 years
Figure 2 Probability of survival in the patients aged Ͻ50 years and those with an age of у50 years. P ϭ 0.44. No. patients at risk > 50 years No. patients at risk < 50 years <50 years >50 years Figure 3 Probability of leukemia-free survival (LFS) in the patients aged Ͻ50 years and those with an age of у50 years. P ϭ 0.34. No. patients at risk > 50 years No. patients at risk < 50 years < 50years
> 50years
Figure 4 Probability of current LFS in the patients aged Ͻ50 years and those with an age of у50 years. P ϭ 0.40. Table 2 Two-year probability of leukemia-free survival (LFS) for disease categories
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2-year probability of LFS (95% CI)
AML-CR1 (n ϭ 52) 53% (39-67%) ALL-CR1 (n ϭ 34) 64% (48-80%) CML-CP1 (n ϭ 45) 61% (46-76%)
AML vs ALL: P ϭ 0.32; AML vs CML: P ϭ 0.40; ALL vs CML: P ϭ 0.82.
for our two age-cohorts consisting of patients Ͻ50 or у50 years. In the Ringdén study, 2-year overall probability of TRM for early leukemia was 38% (95% CI, 35% to 41%) and 2-year probability of TRM in the 40 patients aged у50 years was 41% (95% CI, 23% to 61%). In our patients these figures were 24% (95% CI, 16% to 32%) and 13% (95% CI, 0% to 30%), respectively. The majority of the patients described by Ringdén et al had received unmanipulated grafts and as a consequence TRM due to GVHD and GVHD-related causes was higher than in our patients who were all recipients of T cell-depleted grafts. Despite the addition of anthracyclines to the conditioning regimen, overall TRM and TRM in the patients aged у50 years was within the range of that reported in other studies on recipients of T cell-depleted grafts for early leukemia. [15] [16] [17] Recently, new approaches to allografting have been developed and consist of conditioning regimens that were reduced in intensity. These less intensive regimens are claimed to be suitable for older patients. 7, 8 The 15 patients reported by Giralt et al 7 were not candidates for myeloablative therapy because of age у50 years (n ϭ 13) or organ dysfunction (n ϭ 2). Median age was 59 (range, 27-71) years. Indications for transplantation with stem cells were advanced leukemias or myelodysplastic syndromes. All but two donors were HLA-identical siblings. Four of 15 patients (27%) died from TRM. Khouri et al 8 transplanted 15 patients ineligible for high-dose myeloablative regimens because of age Ͼ50 years (n ϭ 13) or comorbidities (n ϭ 2). All patients were heavily pretreated for lymphoid malignancies. Donors were HLA-identical siblings. Six of 15 patients (40%) died from TRM. A major drawback of this approach is that the infusion of lymphocytes in transplants early after BMT is associated with a high morbidity and mortality related to GVHD. 18, 19 However, in selected patients nonmyeloablative stem cell transplantation and cell therapy may be an alternative to conventional transplantation. Slavin et al 20 transplanted 26 patients aged from 1 to 61 years (median, 31) after conditioning with a combination of fludarabine, ATG and busulfan or cyclophosphamide. 20 All patients had standard indications and would have been considered eligible for conventional myeloablative transplantation. CsA alone was given as prophylaxis for GVHD. All but one donor of G-CSF-mobilized blood stem cells were HLA-identical siblings. Four of 26 patients (15%) died, all from GVHD.
In the present analysis we have shown that outcome of T cell-depleted transplantation in patients aged у50 years and after conditioning with an intensified conditioning regiBone Marrow Transplantation men can compete with that in younger patients. Both in the younger and older age group, TRM was within the range of that observed in recipients of T cell-depleted grafts from the literature. The results of transplantation after nonmyeloablative regimens should be compared with that obtained with T cell-depleted grafts, preferably in a prospective, randomized setting. The same may be true for the comparison of T cell-depleted allografting vs T cell-replete allografting in a population of good-risk leukemia after conditioning with a myeloablative regimen.
